Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis

Psoriatic Arthritis Clinical Trial

Official title:

Anxiety and Depression in Patients With Psoriatic Arthritis: Prevalence and Characteristics

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00884468
• Other study ID #: 0881A5-4468
• Status: Completed
• Phase: N/A
• First received: April 16, 2009
• Last updated: May 26, 2009
• Start date: May 2008
• Est. completion date: December 2008

Study information

• Verified date: May 2009
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Comité Ético de Investigación Clínica
• Study type: Observational

Clinical Trial Summary

This is an epidemiological non-interventional study assessing the prevalence of anxiety and/or depression disorders in patients suffering from Psoriatic Arthritis (PsA) in Spain.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 384
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Patients both genders over 18 years old

• Patients with PsA diagnosis

Exclusion criteria:

• Patients with PsA that suffer from other rheumatologic diseases or non-concomitant rheumatologic diseases that the investigator considers not to be appropriate for the study.

• Patients with any medical or physical condition (cognitive damage or difficulties for understanding) that create difficulties for reading and completing the questionnaires described in the protocol.

• Patients that in the study period are taking part in another clinical trial.

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic
• Psoriatic Arthritis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of anxiety and/or depression disorders in patients suffering from PsA in Spain as measured by the Hospital Anxiety and Depression Scale (HAD)		12 months	No
Secondary	To assess the relation between the PsA severity and the presence of anxiety and/or depression disorders in patients suffering from PsA in Spain.		12 months	No